Navigation Links
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Date:2/11/2008

Jean-Frederic Viret, Ph.D. Promoted to Vice President and Chief Financial

Officer; Richard P. Powers to Transition to Consultant Role

SOUTH SAN FRANCISCO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported 2007 fourth quarter and year-end financial results and accomplishments and outlined its objectives for 2008 based on commercialization plans for FDA-approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, as well as clinical development milestones for Adlea(TM), the company's long-acting, localized, non-opioid analgesic drug candidate.

"We are preparing on multiple fronts for a successful commercial introduction for Zingo in the second quarter by driving product demand through multiple initiatives and direct contact with our target customers," said John P. McLaughlin, chief executive officer of Anesiva. "We also have a very active clinical program with Adlea that includes two ongoing Phase 2 trials in post-surgical pain as well as plans to advance into two Phase 3 registration trials in post-surgical indications in the first half of 2008."

Recent Highlights and Accomplishments

Anesiva continued to execute on its corporate, commercial and clinical milestones in late 2007 and early 2008:

Zingo

-- Hired sales force of 15 regional account managers (RAMs) and two

directors targeting key pediatric hospitals to commercialize Zingo for

the approved patient population (three to 18 years of age). The RAMs

completed training and went into their territories at the end of

January. The Anesiva sales force will focus their efforts on creating

demand by educating nurses and physici
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Anesiva Appoints Daniel Janney to Board of Directors
2. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
3. Anesiva Announces Completion of Common Stock Offering
4. Anesiva Raises $45 Million in Common Stock Offering
5. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
6. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... , Nov. 27, 2014 ... the "Global Palmitic Acid Industry Report 2014" ... The Global Palmitic Acid Industry ... the current state of the global palmitic acid industry. ... the industry including definitions, classifications, applications and industry chain ...
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... The North America Thermal Protective Clothing Market ... analysis of the growth trends and revenue forecasts. ... by 2018, growing at a CAGR of 7.1% ... TOC of the North America Thermal Protective Clothing ... in-depth analysis and industry segmentation supported by various ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2
... May 11, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... ended March 31, 2009. Arena reported a net loss allocable ... $50.6 million, or $0.68 per share, compared to a net ... 2008 of $55.0 million, or $0.75 per share. "Receiving the ...
... Inc. (Nasdaq: IDIX ) announced today that Idenix ... Bank 2009 Health Care Conference on Monday, May 18, 2009 ... and archived webcast of the company presentation can be accessed ... www.idenix.com . Please log in approximately ...
... 18, 2009 SAN DIEGO, May 11 Neurocrine Biosciences, ... Kevin Gorman, President and Chief Executive Officer of Neurocrine ... Annual Health Care Conference in Boston. The live presentation ... Eastern Time (ET)/2:05 p.m. Pacific Time (PT). The ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference 2
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Hospital (MGH) Cancer Center have identified a subgroup of ... drug cisplatin, rarely used in the treatment of breast ... of this sensitivity, which may help identify patients most ... will be tested in a clinical trial anticipated to ...
... delivered into the tumors of stage 4 lung cancer ... phase I clinical trial at The University of Texas ... found to be active in the metastatic non-small cell ... first-in-human study and we've seen an exciting proof of ...
... cut back on the amount of salt in their diet could ... to a report on bmj.com today. , Researchers in ... risk of death from cardiovascular disease by up to a fifth. ... diseases linked to the heart or arteries, for example a stroke ...
Cached Biology News:Molecular signature may identify cisplatin-sensitive breast tumors 2Molecular signature may identify cisplatin-sensitive breast tumors 3Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer 2Eating less salt could prevent cardiovascular disease 2
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
Biology Products: